Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-02-11

Clinical Trial Update: Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the malaria vaccine Pfs25-EPA/Alhydrogel has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pfs25-EPA/Alhydrogel

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 1 | Status: COMPLETED